Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone and dexborneol in newly diagnosed untreated Parkinson's disease with depressive symptoms
ChiCTR2200056774Phase 4Recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of edaravone and dexborneol in Parkinson's disease (PD) (2 arms), sponsored by Affiliated Brain Hospital of Nanjing Medical University. Primary endpoints: Unified Parkinson's Disease Rating Scale and Hamilton Depression Scale. Started Feb 2022; status: recruiting.
02
Drugs
edaravonedexborneol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2200056774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056774.